Linde LLC and IMA Life North America will host a webinar tomorrow titled “Lessons Learned for Successful Induced Nucleation at Production Scale: Review and Scale-up Case-Study Using VERISEQ® Nucleation.”

The webinar will be held April 22 at 4:30 p.m. (GMT+1), and the companies are inviting pharmaceutical manufacturers involved in freeze drying biotech and non-biotech derived products – vaccines, peptides, proteins, solutions, etc. – to take part as the results of a study testing proprietary controlled nucleation technology on a production scale are recealed.

“This study is the first demonstration of the success in applying controlled nucleation to one of the largest in the industry – 56 square-meter freeze dryer operating at a load of 195,960 vials,” said Eugene Wexler, Linde’s Senior Project Manager, Chemicals and Environment, Applications Technology Americas.

“Until now, there has been no commercially feasible way of achieving uniform ice nucleation on a production scale,” Wexler added.

VERISEQ nucleation technology was introduced in 2012 and controls formation of ice crystals using a sterile cryogenic ice fog, resulting in enhanced lyophilization (freeze drying) cycles and improved product characteristics.

The invite for the webinar can be found here: